Immunotherapy plus chemo shows promise for rare cervical cancer
NCT ID NCT07336147
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether adding the immunotherapy drug dostarlimab to standard chemotherapy and radiation can help women with a rare and aggressive type of cervical cancer called small cell neuroendocrine carcinoma. About 45 women with early to advanced stages of the disease will receive the combination treatment. The goal is to see if this approach improves how long women live without their cancer getting worse, compared to past results with standard treatment alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dostarlimab (an immunotherapy drug) combined with cisplatin and etoposide (chemotherapy) and radiotherapy
What this could lead to
If successful, this could offer a more effective treatment option for a rare and aggressive cervical cancer, potentially improving survival rates.
What could go wrong
This is a small Phase 2 trial with only 45 participants, so results may not apply to all patients. The combination therapy may cause significant side effects, and the improvement in survival is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FEMALE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital, Linkou Branch
RECRUITINGTaoyuan, Taiwan, 333, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••